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as a consequence of deﬁciency of ADAMTS13 (a plasma metallo-
protease that regulates von Willebrand factor size and reduces its
platelet adhesive activity) and provide a clinical case history to
support our hypothesis.
A patient with non-cirrhotic intrahepatic portal hypertension
(NCIPH), ulcerative colitis and celiac disease developed symp-
toms of PPH, which had advanced beyond levels which would
have made her an eligible candidate for liver transplantation
(mean pulmonary artery pressure (PAP) 49 mmHg). She was
known to have severe ADAMTS13 deﬁciency, which we
considered to be causative of, or contributory to her NCIPH. We
postulated that increasing porto-systemic shunting associated
with advancing portal hypertension would make the next
encountered vascular bed, the lung, susceptible to the pathogenic
process that was previously conﬁned to the portal system, with
pulmonary hypertension as its consequence. Her pulmonary
artery pressures fell signiﬁcantly during the next year on weekly
replacement of plasma ADAMTS13 by infusions of fresh frozen
plasma and conventional drug treatment of her pulmonary
hypertension. Her pulmonary artery pressures had fallen to
acceptable levels when, in response to platelet infusion, it rose
precipitously and dangerously.
The sequence strongly supports our hypothesis that PPH is a
consequence of ADAMTS13 deﬁciency and is caused by platelet
deposition in afferent pulmonary vessels.
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by Elsevier B.V. All rights reserved.Journal of Hepatology 20
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signiﬁcantly worsens the prognosis [1]. Despite extensive studies
including genotyping of more than 1000 polymorphisms in 93
candidate genes [2], the pathogenic relationship between liver
disease and PPH remains unclear. Current consensus is that loss
of the liver as a detoxifying organ allows deleterious substances
from the portal system to reach the pulmonary circulation. Liver
transplantation may lead to resolution of PPH, but severe PPH is
considered a contraindication to transplantation due to unaccept-
ably high peri-operative mortality. Many patients die peri-opera-
tively of unanticipated, acute right ventricular failure and
cardiopulmonary collapse of unknown cause [3].
ADAMTS13 is a metalloprotease that circulates in plasma and
whose only known substrate is von Willebrand factor (VWF).
VWF is an adhesive glycoprotein secreted by the vascular endo-
thelium in an ultra large multimeric form (ulVWF), which unfolds
under high shear stress thus exposing sites to which platelets
avidly adhere and aggregate to promote haemostasis. Normally,
this ulVWF is rapidly cleaved by ADAMTS13, enabling release of
smaller, less active forms of VWF into the circulation. Deﬁciency
of ADAMTS13 results in a loss of VWF regulatory control and
vessel occlusion by hyper-reactive ulVWF and platelet thrombi,
as seen in the disease thrombotic thrombocytopenic purpura
(TTP), which has high mortality in the absence of rapid treatment
[4].
We present the case of a patient with sustained ADAMTS13
deﬁciency, NCIPH, and PPH who developed a sudden increase in
pulmonary artery pressure and acute right ventricular failure
following a platelet transfusion. This case, along with recent
research from our group showing sustained low plasma levels
of ADAMTS13 in patients with NCIPH [5], leads us to present a
new hypothesis on the pathogenesis of PPH and highlights the
danger of platelet transfusion as a likely cause of the acute
cardiopulmonary collapse seen in this group of patients.Case report
A 38-year-old Caucasian lady was referred to our liver unit on
account of worsening liver function tests. She had been diag-
nosed with celiac disease and ulcerative colitis, having previously13 vol. 58 j 827–830
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been investigated for long standing thrombocytopenia (50–
95  109/L) and splenomegaly for which no cause had been
found, despite multiple haematological investigations, including
bone marrow aspiration. Her main complaint was of exertional
dyspnoea. Lung function tests showed normal spirometry and
lung volumes but reduced gas transfer (TLCO 4.6 mmol min1 -
kPa1 (3.55 SD) KCO 0.94 mmol min1 kPa1 L1 (4.22 SD)).
She also complained of easy bruising and menorrhagia. Ultra-
sound showed a small liver, patent portal vein and enlarged
spleen (19 cm). Wedged hepatic vein pressure gradient was
8 mmHg. Transjugular liver biopsy showed retained vascular
relationships, however, portal tracts were very small. Review of
an earlier liver biopsy performed elsewhere showed nodular
regenerative hyperplasia and sinusoidal dilatation, conﬁrming
the likely diagnosis of NCIPH.
One year later, her exercise tolerance had reduced and trans-
thoracic echocardiogram showed her pulmonary artery systolic
pressure (PASP) had markedly increased to 76–81 mmHg. She
was therefore evaluated with a view to being listed for liver
transplantation and underwent a Swann Ganz catheter study,
which showed a PASP of 95 mmHg with a mean PAP of 49 mmHg.
The right ventricle was mildly dilated and hypertrophied. It was
decided that liver transplantation could no longer be considered
because of its excessive risks in patients with such marked pul-
monary hypertension.
ADAMTS13was investigated in this patient since we had found
decreased levels in other patients with NCIPH [5]. Citrated plasma
was collected and promptly centrifuged before being stored at
80 C. ADAMTS13 activity (collagen binding assay), antigen and
IgG anti-ADAMTS13 were measured by ELISA assays [5].
At all time points, ADAMTS13 activity levels in peripheral
blood were very low (6%; on a single occasion (normal range
55–160%)) or undetectable (<5%) on four occasions over a one-
year period (Table 1A). This sustained low plasma ADAMTS13
activity was associated with reduced ADAMTS13 antigen levels
(although in small excess over activity) (Table 1A), in the absence
of IgG anti-ADAMTS13 antibodies. We twice conducted an
ADAMTS13 half-life study using fresh frozen plasma (FFP) as an
ADAMTS13 source, which conﬁrmed that her low level of ADAM-
TS13 was not due to excessive consumption of the protein
(Table 1B).
As discussed below, we hypothesised that her ADAMTS13
deﬁciency was a crucial factor in the development of porto-
pulmonary hypertension. In light of this, she received weekly
transfusions of FFP (containing ADAMTS13), as well as conven-
tional therapies (nebulised Iloprost 7.5 mg QDS and Sildenaﬁl
100 mg tds) for pulmonary hypertension, for a period of eighteen
months, during which her pulmonary pressures gradually
declined and her ADAMTS13 levels were maintained at 19–38%.
It was decided to proceed with liver transplantation.
On the morning of surgery, Swann Ganz catheterisation
showed a PAP of 52/17 (mean 34 mmHg) and her CVP was mea-
sured at 3 mmHg. In response to oozing from port sites, she was
given 2 units of platelets as well as an Iloprost nebuliser. One and
a half hours after platelet infusion, repeat measurement showed a
PASP of 89/45 (mean 65–68) mmHg. CVP had increased to
15 mmHg (Table 2). Echocardiogram showed a sluggish and
markedly dilated right ventricle and empty left ventricle. It was
decided not to proceed with liver transplantation and she was
transferred to the intensive care unit. At this time, her ADAMTS13
activity was 25% (antigen 52%). She was given further FFP and828 Journal of Hepatology 201fortunately survived. Amelioration of her pulmonary arterial
pressures has subsequently been sustained for 3 years during
which she has received weekly FFP, and in which she has not
developed any signs of liver failure.Discussion
It has been shown that platelet transfusion is a major indepen-
dent risk factor for mortality in liver transplantation, with sur-
vival reduced from 92% to 74% at 1 year, and that acute lung
injury was the only statistically signiﬁcant mechanism identiﬁed
to account for this observation [6]. Earlier, post-mortem studies
of porto-pulmonary hypertension demonstrated recanalising
intravascular thrombi in the small pulmonary arteries and postu-
lated that these were caused by thromboemboli [7,8]. However,
no source of thromboemboli could be found, and these lesions
were redescribed as plexiform lesions mimicking the colander
lesions of recanalised thrombi [9].
Sankey et al. studied the lung pathology of all patients dying
peri-operatively in a three- and a half-year period, at one centre
[10]. There were notable differences between those who died
during liver transplantation and those who were undergoing
non-transplant procedures. Sections of lung from liver transplant
recipients, particularly those who had died suddenly during the
operation, showed extensive platelet aggregates occluding small
arterioles and alveolar capillaries of all lobes. A sudden fall in
platelet count and rise in pulmonary artery pressure were com-
monly recorded.
In our case, it is clear that the acute rise in pulmonary artery
pressure immediately followed the platelet transfusion. There
have been many hypotheses put forward to explain this phenom-
enon including build-up of platelet micro-aggregates and other
deleterious substances in stored donor platelets [6]. We propose
that the reason these patients are prone to develop widespread
pulmonary platelet aggregation is due to abnormality in the
physiological control of platelet adherence which, as our case
strongly suggests, may involve ADAMTS13 deﬁciency. If ADAM-
TS13 is not available, ulVWF secreted from the vascular endothe-
lium survives in the circulation and is able to promote the
formation of platelet-rich thrombi in the microcirculation. In
acute idiopathic TTP, ADAMTS13 activity is usually less than
10%; however, subjects with mild to moderate congenital deﬁ-
ciency (11–55%) can often lead a normal life in the absence of
haemostatic challenge, only developing TTP after exposure to cer-
tain triggers such as infection or pregnancy.
In TTP the liver and lungs are relatively spared, the liver’s
sparing being attributable in part to the ﬁltering of emboli from
the 70% of its blood supply, which has traversed capillaries within
the intestine and spleen. The hepatic stellate cell is the major
source of newly synthesized ADAMTS13 [11] and in TTP the entry
into hepatic venous blood of de novo synthesized ADAMTS13
appears sufﬁcient to protect the next vascular bed, the pulmon-
ary capillaries. The novel paradigm we propose of disease causa-
tion in NCIPH and PPH, diminished production of ADAMTS13
rather than its enhanced clearance, provides the reverse corollary
and accounts for the inverted susceptibility ratio of various
organs.
Secondary ADAMTS13 deﬁciency is known to occur with
advancement of liver disease [11]. We have reported ADAMTS13
deﬁciency in a series of patients with NCIPH [5], a cohort in3 vol. 58 j 827–830
Table 1. Serial plasma levels of ADAMTS 13 antigen and activity over a 12-month period of observation, reﬂecting its spontaneous production (A) and on 2 occasions
following its supplementation by infusion of fresh frozen plasma (B). (A) Plasma ADAMTS13 activity levels were close to, or below the lower limit of detection of 5% over
a 12-month period. No gradient could be identiﬁed between concentrations in hepatic vein and mixed venous blood. NR, normal range. (B) Plasma ADAMTS13 was
measured immediately before, during, and following infusion with four units of FFP on two occasions at baseline and following treatment with weekly infusion of FFP. The
initial 24-h study showed no support for the notion that deﬁciency was due to excessively rapid clearance of ADAMTS13 from plasma, as is seen in acquired TTP. The second
study conﬁrmed that detectable levels of ADAMTS13 were being maintained beyond 72 h and up to one week (baseline value) by the ongoing regimen involving weekly
infusions of three units of FFP.
Month Activity Antigen
NR 55-160% NR 64-136%
1 Peripheral vein <5 39
8 Peripheral vein   6 36
11 Peripheral vein <5
12 Hepatic vein <5 39
Right atrium <5 38
Time Activity Antigen Activity  Antigen
At baseline Following treatment
Pre-infusion <5 39 27 34 
2 h 16 51 38 41
24 h 10 40 46
48 h 36 43
72 h 45 47
A B
Table 2. Pulmonary pressures measured by echocardiogram or cardiac catheterisation over a three-year period.
Month Time Procedure PASP PAP Mean PAP PCWP PVR CVP
0 Echo 30-35
12 Echo 76-81
18 Catheter 95 49
30 7 am Catheter 57/17 34 -1 293 3
2 units platelets given
9 am Catheter 89/45 65-68 21 15
36 Catheter 38 14 236
PASP, pulmonary artery systolic pressure; PAP, pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance; CVP, central
venous pressure.
JOURNAL OF HEPATOLOGYwhom the absence of intrinsic liver disease argued strongly that
the ADAMTS13 deﬁciency was primary and pathogenic, not a
consequence of the liver abnormality. VWF is not normally
expressed on hepatic sinusoidal endothelium but is produced in
response to stimulation by TNF alpha and various other cytokines
[12]. We reported an increase in the incidence of celiac disease in
patients with NCIPH [13] and now postulate that in patients with
primary ADAMTS13 deﬁciency, noxious venous efﬂuent from
such gut disorders can perturb the vWF: ADAMTS13 ratio within
the mesenteric circulation, so as to cause microvascular occlusion
in the terminal radicles of the portal vein, which is the typical his-
tological ﬁnding in NCIPH [14].
Further to this, an association between NCIPH and PPH has
been reported and we propose that the same mechanism of dis-
ease applies [15]. Before liver disease has progressed to an
advanced stage, the lungs will be protected from the above pro-
cess by the ﬁltering of portal blood within the liver along with
its residual synthesis of ADAMTS13, adjacent to and in series with
the pulmonary vascular bed. As liver disease advances, loss of
residual ADAMTS13 synthesis combined with porto-systemic
shunting will expose the previously protected lungs to the same
pathogenic conditions previously present in the portal vein (note
that our patient had both celiac disease and ulcerative colitis).
We postulate that the combination of these factors may lead to
expression of abnormal amounts of ulVWF on pulmonary vascu-
lar endothelium.Journal of Hepatology 201Chronic excessive platelet binding to this ulVWF would not
only lead to simple micro-occlusion but also aggravate the
already perturbed pulmonary vascular homeostasis by release
of a host of pro-inﬂammatory and vasoconstrictive substances
as has been extensively reported in the literature [16]. Over time,
this could produce PPH in its chronic progressive form. Impor-
tantly however, this theory would also explain why a bolus plate-
let transfusion delivered into the venous circulation could cause
acute occlusion of the primed pulmonary vascular bed and pre-
cipitate acute right ventricular failure as happened in our patient.
When porto-pulmonary hypertension is a contraindication to
liver transplantation, ADAMTS13 replacement could be used to
reverse the above process and reduce pressures to an acceptable
level. This can be accomplished with FFP or certain intermediate
purity factor VIII concentrates, which have been used successfully
in congenital TTP [17]. During surgery, avoidance of platelet
transfusion until plasma ADAMTS13 activity has been normalised
should avoid fatalities from acute pulmonary hypertension.
We have used the example of NCIPH because it illustrates the
proposed pathogenic mechanism in its purest form [5]. However,
ADAMTS13 deﬁciency can occur in patients with any type of liver
disease and therefore the hypothesised mechanism of PPH is not
exclusive to NCIPH. Further work is needed to test this hypothe-
sis, including measurement of ADAMTS13 activity levels in a lar-
ger number of patients with PPH.3 vol. 58 j 827–830 829
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